Scenarios that move HALO
Halozyme Therapeutics, Inc. - Common Stock
Scenarios that move HALO: 4 analyses, 3 positive, 1 negative.
- · argenx meets primary endpoint in Phase II celiac disease study — ▼ · impact -35 · confidence low · horizon quarters
- · HALO wins court order blocking Merck's European Keytruda SC — ▲ · impact +88 · confidence high · horizon immediate
- · Pharma stock soars 150% after injectables deal with Novo — ▲ · impact +56 · confidence medium · horizon immediate
- · Ascendis announces planned $400 million share repurchase program — ▲ · impact +9 · confidence low · horizon quarters